Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 301-147-1
Published by: Babson College
Originally published in: 2001
Version: 26 June 2001
Length: 17 pages
Data source: Published sources

Abstract

This is the second of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes Biogen, one of the top biotechnology firms worldwide. Discussion covers activity during the period 1998-1999 including key products, research and development, marketing, competition, and financials. Based in Massachusetts, Biogen rose to success as a result of expertise in molecular biology, cell biology, immunology, and protein chemistry. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.
Location:
Industry:
Size:
USD558 million
Other setting(s):
1999

About

Abstract

This is the second of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes Biogen, one of the top biotechnology firms worldwide. Discussion covers activity during the period 1998-1999 including key products, research and development, marketing, competition, and financials. Based in Massachusetts, Biogen rose to success as a result of expertise in molecular biology, cell biology, immunology, and protein chemistry. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.

Settings

Location:
Industry:
Size:
USD558 million
Other setting(s):
1999

Related